Stockreport

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at E [Read more]